What is Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (1762.TW) StockRank?

MoatMap's StockRank for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) is 76/100, with a Buy signal. This is a composite score combining Quality (44), Value (46), and Momentum (74) factor ranks across MoatMap's 20,000+ stock universe.

Does Chunghwa Chemical Synthesis & Biotech Co., Ltd. have an economic moat?

Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) has a Quality factor score of 44/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Chunghwa Chemical Synthesis & Biotech Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) is Buy, based on a StockRank of 76/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Chunghwa Chemical Synthesis & Biotech Co., Ltd. in?

Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) operates in the Healthcare sector, specifically the Biotechnology industry (Taiwan).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

1762.TW

BUYFLAG

Chunghwa Chemical Synthesis & Biotech Co., Ltd. · Healthcare · Taiwan · $87M · Avg Vol: $964K/d

StockRank

P/E (TTM)

—

ROE

-4.9%

D/E

0.3x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Chunghwa Chemical Synthesis is a Taiwanese API manufacturer with CDMO capabilities. While it stands to benefit from the CDMO pricing power cycle and supply chain localization away from mainland China, its small scale and localized geopolitical risks prevent a high-conviction buy.

COMPANY DESCRIPTION

Chunghwa Chemical Synthesis & Biotech Co., Ltd. develops and manufactures Active Pharmaceutical Ingredients (APIs) via chemical synthesis and biotechnology. The company is an FDA-approved API manufacturer serving global pharmaceutical companies, specializing in immunosuppressants and cardiovascular drugs. It operates as a high-value niche biotech player with strong R&D capabilities and a track record of international regulatory approvals.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	66.9M	65.9M	42.6M	25.4M	-27.6%
EPS	0.16	0.19	0.11	0.03	—	-43.1%
Shares	—	77.6M	77.6M	77.6M	76.9M	-0.8%
Debt	—	19.1M	38.2M	27.1M	25.5M	10.1%
Equity	—	100.9M	105.9M	106.1M	97.5M	-1.1%
Op CF	—	23.2M	-2.1M	14.8M	4.5M	-42.1%
Inv CF	—	-11.9M	-14.6M	-3.2M	-2.0M	—
Fin CF	—	-8.0M	15.7M	-13.1M	-2.7M	—

PRICE (1Y)+1.1%

SMA 50SMA 200

$1.18

RSI (14)

39.0

52W High

$1.41

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-6.0%37.9

ROE

-4.9%39.5

GP/Assets

1.9%13.8

Op. Margin

22.0%85.1

FCF/Assets

4.1%66.5

Piotroski

430.3

Int. Cover

-14.3x20.3

D/E Ratio

0.25x47.6

Current Ratio

3.02x53.5

Value

P/E (TTM)

—N/A

EV/EBITDA

-88.0x25.0

P/FCF

491.2x68.5

P/B

0.9x87.4

P/S

2.8x58.4

Div Yield

—N/A

Momentum

52W High %

84%72.5

RS 6M

-15%51.6

SMA 50/200

1.23x90.2

EPS Rev 4W

+0.5%75.1

EPS Rev 12W

—N/A

EPS Improve

—75.0

Q Growth

1138%97.6

FUNDAMENTALS

Market Cap

$87M

P/E (Forward)

78.6x

Gross Margin

8.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 1762.TW are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
1762.TW	Chunghwa Chemical Synthesis & Biotech Co., Ltd.(you)	$87M	76	BUY
8279.TWO	Syngen Biotech Co.,Ltd.	$82M	87	STRONG BUY
1760.TW	Panion & Bf Biotech Inc.	$163M	77	BUY
1733.TW	Apex Biotechnology Corp.	$93M	91	STRONG BUY
4167.TWO	Savior Lifetec Corporation	$193M	80	STRONG BUY
4162.TWO	PharmaEngine, Inc.	$256M	74	BUY
1734.TW	Sinphar Pharmaceutical Co.,Ltd.	$193M	85	STRONG BUY
4728.TWO	Sunmax Biotechnology Co., Ltd.	$648M	78	BUY
6634.TWO	Sinew Pharma Inc.	$143M	35	SELL
4130.TWO	Genovate Biotechnology Co., Ltd.	$109M	29	SELL

Peer medians: ROE 3.6% · P/E 16.2x · Gross margin 42.1%

Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) — Stock Score Summary

Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) has a MoatMap StockRank of 76/100 based on Quality (44/100), Value (46/100), and Momentum (74/100) factor scores. The current signal is BUY. Chunghwa Chemical Synthesis is a Taiwanese API manufacturer with CDMO capabilities. While it stands to benefit from the CDMO pricing power cycle and supply chain localization away from mainland China, its small scale and localized geopolitical risks prevent a high-conviction buy.

Key Financial Metrics

Price	$1.18
Market Cap	$87M
P/E (Forward)	78.56
Price/Book	0.86
Return on Equity	-4.9%
Return on Invested Capital	-6.0%
Debt/Equity	25.28
Gross Margin	8.3%
Operating Margin	22.0%
Revenue Growth	87.2%
Free Cash Flow	$177K

Chunghwa Chemical Synthesis & Biotech Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (Taiwan).

Frequently Asked Questions

What is Chunghwa Chemical Synthesis & Biotech Co., Ltd.’s (1762.TW) StockRank?: MoatMap’s StockRank for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) is 76/100, with a Buy signal. It is a composite of Quality (44), Value (46), and Momentum (74) factor ranks across MoatMap’s 20,000+ stock universe.
Does Chunghwa Chemical Synthesis & Biotech Co., Ltd. have an economic moat?: Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) has a Quality factor score of 44/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Chunghwa Chemical Synthesis & Biotech Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) is Buy, based on a StockRank of 76/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Chunghwa Chemical Synthesis & Biotech Co., Ltd. in?: Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) operates in the Healthcare sector, specifically the Biotechnology industry (Taiwan).